Evidence map›Paper›PMID 27608278›Full record

ArticleBrain pathology (Zurich, Switzerland)2017

Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu-Hakola disease: lesion staging and dynamic changes of axons and microglial subsets.

Kiyomitsu Oyanagi, Michiaki Kinoshita, Emi Suzuki-Kouyama, Teruhiko Inoue, Asa Nakahara, Mika Tokiwai, Nobutaka Arai, Jun-Ichi Satoh, Naoya Aoki, Kenji Jinnai and 14 more

Open access · greenAbstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Macrophage transplantation rescues RNASET2-deficient leukodystrophy by replacing deficient microglia in a zebrafish model.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  7. Microglia in Neurodegenerative Diseases.Advances in neurobiology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. The Primary Microglial Leukodystrophies: A Review.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 15 institutions in 1 country.

Kiyomitsu OyanagiDivision of Neuropathology, Department of Brain Disease Research, Shinshu University School of Medicine, Nagano, Japan.
Michiaki KinoshitaDepartment of Neurology, Suwa Red Cross Hospital, Nagano, Japan.
Emi Suzuki-KouyamaDivision of Neuropathology, Department of Brain Disease Research, Shinshu University School of Medicine, Nagano, Japan.
Teruhiko InoueDepartment of Neurology, Daigo Hospital, Miyazaki, Japan.
Asa NakaharaDivision of Neuropathology, Department of Brain Disease Research, Shinshu University School of Medicine, Nagano, Japan.
Mika TokiwaiDivision of Neuropathology, Department of Brain Disease Research, Shinshu University School of Medicine, Nagano, Japan.
Nobutaka AraiTokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Jun-Ichi SatohDepartment of Bioinfomatics and Molecular Neuropathology, Meiji Pharmaceutical University, Tokyo, Japan.
Naoya AokiTokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Kenji JinnaiDepartment of Neurology, National Hospital Organization Hyogo-Chuo-Hospital, Hyogo, Japan.
Ikuru YazawaLaboratory of Research Resources, Research Institute, National Center for Geriatrics and Gerontology, Aichi, Japan.
Kimihito AraiDepartment of Neurology, National Hospital Organization Chiba-East Hospital, Chiba, Japan.
Kenji IshiharaDepartment of Neurology, Showa University School of Medicine, Tokyo, Japan.
Mitsuru KawamuraDepartment of Neurology, Showa University School of Medicine, Tokyo, Japan.
Keisuke IshizawaDepartments of Neurology and Pathology, Saitama Medical University, Saitama, Japan.
Kazuko HasegawaDepartment of Neurology, Sagamihara National Hospital, Kanagawa, Japan.
Saburo YagisitaKanagawa Rehabilitation Center, Kanagawa, Japan.
Naoji AmanoDepartment of Psychiatry, Shinshu University School of Medicine, Nagano, Japan.
Kunihiro YoshidaDivision of Neurogenetics, Department of Brain Disease Research, Shinshu University School of Medicine, Nagano, Japan.
Seishi TeradaDepartment of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Mari YoshidaDepartment of Neuropathology, Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.
Haruhiko AkiyamaTokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Yoshio MitsuyamaDepartment of Neurology, Daigo Hospital, Miyazaki, Japan.
Shu-Ichi IkedaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan.
Shinshu University · JPTokyo Metropolitan Institute of Medical Science · JPAichi Medical University · JPChiba East Hospital · JPKanagawa Rehabilitation Hospital · JPMeiji Pharmaceutical University · JPNational Center for Geriatrics and Gerontology · JPNational Hospital Organization · JPNational Sagamihara Hospital · JPNiigata University · JPOkayama University · JPSaitama Medical University · JPShowa University · JPSuwa Red Cross Hospital · JPUshio (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The brains of 10 Japanese patients with adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) encompassing hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) and pigmentary orthochromatic leukodystrophy (POLD) and eight Japanese patients with Nasu-Hakola disease (N-HD) and five age-matched Japanese controls were examined neuropathologically with special reference to lesion staging and dynamic changes of microglial subsets. In both diseases, the pathognomonic neuropathological features included spherically swollen axons (spheroids and globules), axon loss and changes of microglia in the white matter. In ALSP, four lesion stages based on the degree of axon loss were discernible: Stage I, patchy axon loss in the cerebral white matter without atrophy; Stage II, large patchy areas of axon loss with slight atrophy of the cerebral white matter and slight dilatation of the lateral ventricles; Stage III, extensive axon loss in the cerebral white matter and dilatation of the lateral and third ventricles without remarkable axon loss in the brainstem and cerebellum; Stage IV, devastated cerebral white matter with marked dilatation of the ventricles and axon loss in the brainstem and/or cerebellum. Internal capsule and pontine base were relatively well preserved in the N-HD, even at Stage IV, and the swollen axons were larger with a higher density in the ALSP. Microglial cells immunopositive for CD68, CD163 or CD204 were far more obvious in ALSP, than in N-HD, and the shape and density of the cells changed in each stage. With progression of the stage, clinical symptoms became worse to apathetic state, and epilepsy was frequently observed in patients at Stages III and IV in both diseases. From these findings, it is concluded that (i) shape, density and subsets of microglia change dynamically along the passage of stages and (ii) increase of IBA-1-, CD68-, CD163- and CD204-immunopositive cells precedes loss of axons in ALSP.

Indexed as

AdultAtrophyAutopsyAxonsBrainFemaleHumansJapanLeukoencephalopathiesLipodystrophyMaleMicrogliaMiddle AgedNeurogliaOsteochondrodysplasiasSubacute Sclerosing PanencephalitisALSPHakolaHDLSlesion stagingmicrogliaNasu

Identifiers

PMID27608278
PMCPMC8029200
OpenAlexW2519159792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.